Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study

Autor: Marinus H. J. van Oers, Sebastian Grosicki, Lukas Smolej, Tommaso Stefanelli, Mark-David Levin, Jaclyn Davis, Fritz Offner, Mario Petrini, Petra Hoever, Hiya Banerjee, Christian H. Geisler

Publikováno v: BLOOD CANCER JOURNAL
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-9 (2019)
Blood cancer journal, 9(12):98. Nature Publishing Group
Blood Cancer Journal

We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29c71ed30d2020e9002d061532af293
https://biblio.ugent.be/publication/8647119

Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans

Autor: Tommaso Miraval, Jasper Dingemanse, Gérard Hopfgartner, Kasra Shakeri-Nejad, Winfried Wagner-Redeker, Alexander Treiber, Matthias Hoch, Petra Hoever

Publikováno v: Drug Metabolism and Disposition. 41:1046-1059

Almorexant [(2R)-2-{(1S)-6, 7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide], a tetrahydroisoquinoline derivative, is a dual orexin receptor antagonist with sleep-promoting properties in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350cc9c10a17e8666f21084f570fdea4
https://doi.org/10.1124/dmd.112.050120

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects

Autor: Federica Alessi, Matthias Hoch, Jasper Dingemanse, Petra Hoever, Rudolf Theodor

Publikováno v: European Journal of Clinical Pharmacology. 69:523-532

Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4). Therefore, a study was conducted to investigate the effects of multiple-dose almorexant on the pharmacokinetics o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724011b1062de405f54f35f855240671
https://doi.org/10.1007/s00228-012-1403-6

Pharmacokinetics and Tolerability of Almorexant in Japanese and Caucasian Healthy Male Subjects

Autor: Matthias Hoch, Joanne Marjason, Federica Alessi, Jasper Dingemanse, Petra Hoever

Publikováno v: Pharmacology. 88:121-126

Background/Aims: The aim of this study was to compare the pharmacokinetics and tolerability of single doses of the dual orexin receptor antagonist almorexant in Japanese and Caucasian healthy male subjects (n = 10 in each group, body weight matched �

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9634241c530e612fc77a31f0216ddd6d
https://doi.org/10.1159/000330098

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Autor: Thomas Weller, Hamed Aissaoui, Francois Jenck, Patrick Hess, Susan Flores, Ralf Koberstein, Petra Hoever, Catherine Brisbare-Roch, Jasper Dingemanse, Michael Scherz, Joop M. A. van Gerven, Oliver Nayler, Sanne de Haas, Stephan Buchmann, Walter Fischli, Martine Clozel, Changbin Qiu, Celia Mueller

Publikováno v: Nature Medicine. 13:150-155

Orexins are hypothalamic peptides that play an important role in maintaining wakefulness in mammals. Permanent deficit in orexinergic function is a pathophysiological hallmark of rodent, canine and human narcolepsy. Here we report that in rats, dogs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d0f77b48bbd6b76562acdaba22e991
https://doi.org/10.1038/nm1544